Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Feb 9, 2026 · Filed Feb 10, 2026
The boss of ResMed| sold $1.37M of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,366,436
Shares × reported transaction price
11 days after results of Jan 29, 2026, 80 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $275.96 on Feb 9, 2026, 35% above its 52-week low and 6% below its high, after a 13% rise over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 80% of the way up, from 251 adjusted closes. 30 trading days earlier: $244.44 on Dec 24, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -0.3% | -0.8% | +0.6% |
| 30 days | -11.1% | -4.3% | -6.8% |
| 90 days | -21.5% | +6.7% | -28.2% |
| 180 days | -15.2% | +11.7% | -27.0% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.